Biocompatible Nanoparticle Composition for Reduced Drug Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic and pharmaceutical compounds face challenges with poor pharmacokinetics and high toxicity, leading to inefficiencies and safety concerns, particularly in targeting specific sites within the body, such as in cancer treatment where normal cells are affected alongside cancer cells.
Innovation Solution
A pharmaceutical composition comprising at least two distinct biocompatible nanoparticles with specific size and surface charge characteristics, administered separately from the compound of interest, optimizes the pharmacokinetic parameters of the compound, reducing toxicity and maintaining or increasing therapeutic benefit, allowing for a lower dose while ensuring equivalent or reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic compounds are administered at standard pharmaceutical doses, then therapeutic benefit is achieved, but toxicity increases
Solution Approach 1:
The patent introduces biocompatible nanoparticles as intermediary carriers to deliver the therapeutic compound. These nanoparticles modify the biodistribution profile of the compound, enabling selective delivery to target sites while reducing exposure to healthy tissues. The nanoparticles act as a mediator between the therapeutic compound and the biological system, achieving therapeutic benefit with reduced toxicity.
Solution Approach 2:
The patent changes the physical and chemical parameters of the therapeutic compound by formulating it with biocompatible nanoparticles. This modification alters the pharmacokinetic parameters including half-life, clearance, and biodistribution, allowing the compound to achieve therapeutic efficacy at lower doses with reduced toxicity.
2Reliability
If therapeutic compounds are administered to achieve optimal concentration, then efficacy is improved, but exposure to healthy cells increases causing toxicity
Solution Approach 1:
The patent applies local quality by enabling the therapeutic compound to concentrate specifically at the target site through nanoparticle-mediated delivery. The biodistribution profile is optimized so that the compound achieves high local concentration at the disease site while maintaining low concentration in healthy tissues, thereby improving efficacy without increasing systemic exposure to healthy cells.
Solution Approach 2:
The biocompatible nanoparticles serve as intermediaries that guide the therapeutic compound to the target site selectively. These nanoparticles modify the compound's interaction with biological systems, enabling preferential accumulation at the disease site and reducing non-specific distribution to healthy tissues.
3Object-affected harmful factors
If compound dosage is reduced to lower toxicity, then safety improves, but therapeutic benefit decreases
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the therapeutic compound through nanoparticle formulation, specifically improving the half-life and biodistribution profile. This allows the compound to maintain therapeutic concentrations at the target site for longer periods, enabling effective therapy even at reduced dosages.
Solution Approach 2:
The biocompatible nanoparticles act as carriers that protect the therapeutic compound from premature clearance and enhance its accumulation at the target site. This intermediary system allows reduced dosing while maintaining therapeutic benefit by improving the compound's delivery efficiency and retention time.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound,to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a firs tbiocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.